Astellas Pharma Inc. Newsletter
-
Zydus and Lupin shares in focus today after Astellas raises Mirabegron guidance by 80%
31 Oct 2025 08:35 GMT
… a drug used to treat overactive bladder.
Global pharma major Astellas Pharma, the … revenue guidance for the drug by nearly 80%, signaling … its recent earnings call, Astellas also indicated that it won … read-through for Indian drugmakers Zydus and Lupin, which …
-
Astellas’ treatment shows promise for menopause symptoms
30 Oct 2025 12:39 GMT
… been encouraging preliminary findings from Astellas Pharma’s ongoing phase 4 OPTION … , Women’s Health–Fezolinetant at Astellas, said: “These new preliminary … findings reinforce Astellas’ commitment to advancing our understanding …
-
New multiple myeloma drugs, Tecvayli and Elrexfio, pass cancer disease panel
30 Oct 2025 09:15 GMT
… .
Opdivo (nivolumab, BMS/Ono Pharmaceutical) and Yervoy (ipilimumab, BMS… ;Ono Pharmaceutical) will have their reimbursement criteria … .
Padcev and Vyloy are new drugs from Astellas. Focusing first on Padcev …
-
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability In Oncology - Financial News Media
28 Oct 2025 07:07 GMT
… therapeutic index of existing cancer drugs, potentially transforming underperforming compounds … Global Shift Toward Smarter Drug Delivery
The pharmaceutical industry is entering … therapeutic options.
Pfizer Inc. and Astellas Pharma U.S. Inc. announced final …
-
<![CDATA[Optogenetics for advanced retinal disease]]>
30 Oct 2025 13:11 GMT
… through the US Food and Drug Administration. Additionally, a phase … is under an investigational new drug (IND)–ready phase for … from Adverum Biotechnologies, Apellis Pharmaceuticals, AsclepiX Therapeutics, Astellas Pharma, Clearside Biomedical, Genentech…
-
ANDA Litigation Settlements - Third Quarter 2025
31 Oct 2025 00:05 GMT
… waive all right to appeal.
Astellas Pharma Inc. v. Ascent Pharms., … Pharms. Corp. v. Eugia Pharma Specialities Ltd., 25-0800 (D … for summary judgment.
HQ Specialty Pharma Corp. v. Amneal Pharms. … attorneys’ fees and costs.
Astellas Pharma Inc. v. Deva Holding …
-
First-line nivolumab-ipilimumab betters colorectal cancer results
30 Oct 2025 22:01 GMT
… other impressive data for drugs like WRN helicase inhibitors … then maybe even adding drugs like that on to … #47;advisory roles with Amgen, Astellas Pharma, AstraZeneca, Bayer, BeiGene, Bristol … Eli Lilly & Co., Fosun Pharma, GSK, Incyte, Merck Serono, …
-
<![CDATA[Considering the Evolution of ARPI Combination Therapy in mHSPC ]]>
28 Oct 2025 21:59 GMT
… even have access or specialty pharmacy so they can’t afford … , Roche, AstraZeneca, Merck, Medscape, UroToday, Astellas Pharma, Genzyme, Foundation Medicine, Bristol Myers …
-
<![CDATA[Study establishes reference data set for GA lesion progression]]>
27 Oct 2025 16:06 GMT
… C5 inhibitor avacincaptad pegol (Izervay; Astellas Pharma Inc.)—that have successfully slowed … avacincaptad pegol then withdrew the drug from the application process.7 …
-
Assertio Announces Leadership Transition
28 Oct 2025 13:15 GMT
… of U.S. Commercial at Astellas Pharmaceuticals Inc., where he grew sales … , and Hospital products. Earlier at Astellas, he built the U.S … . About Assertio Assertio is a pharmaceutical company with comprehensive commercial capabilities …